Micromet: From Europe to the US: The Transformation of Micromet




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Micromet: From Europe to the US: The Transformation of Micromet
Released on: February 01, 2008. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this interview, Fintan Walton talks to Christian Itin, President and CEO of antibody technology company Micromet.
  • Summary
  • Participants
  • Company
In this interview, Fintan Walton talks to Christian Itin, President and CEO of antibody technology company Micromet. Christian talks about how the company was set up in Munich to address one of the gaps in cancer therapy: treatment of the stage of the disease known as micrometastases. He goes on to describe how the decision to launch an IPO in Europe in 2005 was overturned in favour of entering into a reverse merger agreement with CancerVax, through which Micromet was able to forward integrate into the US and gain a listing on Nasdaq. Christian then discusses in some detail Micromet’s antibody technology and the company’s alliances, including the one with MedImmune and the effect that the ensuing merger with AstraZeneca had on the partnership.
Christian Itin has served as CEO of Micromet since March 2004. He joined the company in 1999 as Head of IP and Licensing, then went on to become Vice President of Corporate Development, Vice President Business and Corporate Development and finally Chief Business Officer for 2 years before becoming CEO. Before joining Micromet, Dr Itin was a co-founder of Zyomyx, Inc., a protein chip company. He holds a Diploma in biology and a PhD in cell biology from the University of Basel, Switzerland.
Micromet
Micromet, Inc. is a biopharmaceutical company focused on the development and commercialisation of next-generation antibodies for the treatment of cancer.